Search research articles
Contact Us
Filters
Showing results (281-290 of 306) with videos related to
Page
of 31
Sort By:
Transplantation Direct
|
November 2, 2020
Increase in Alcoholic Hepatitis as an Etiology for Liver Transplantation in the United States: A 2004-2018 Analysis
Nabil Noureddin, Ju Dong Yang, Naim Alkhouri, et al.
Metabolism: Clinical and Experimental
|
June 28, 2024
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019
Pojsakorn Danpanichkul, Kanokphong Suparan, Priyata Dutta, et al.
Communications Medicine
|
October 30, 2024
Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria
Luis Antonio Díaz, Jeffrey V Lazarus, Eduardo Fuentes-López, et al.
Hepatology (Baltimore, Md.)
|
July 5, 2019
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
Quentin M Anstee, Eric J Lawitz, Naim Alkhouri, et al.
JAMA Network Open
|
November 6, 2025
Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes
Jeffrey V Lazarus, Leire Agirre-Garrido, Luis Antonio Díaz, et al.
The New England Journal of Medicine
|
October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Journal of Hepatology
|
March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.
The Lancet. Gastroenterology & Hepatology
|
December 15, 2025
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study
Jeffrey V Lazarus, Leire Agirre-Garrido, Trenton M White, et al.
The Lancet. Gastroenterology & Hepatology
|
March 24, 2022
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
Stephen A Harrison, Manal F Abdelmalek, Guy Neff, et al.
The New England Journal of Medicine
|
February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
Page
of 31
Search research articles
Search
Showing results (281-290 of 306) with videos related to
Sort By:
Page
of 31
Transplantation Direct
|
November 2, 2020
Increase in Alcoholic Hepatitis as an Etiology for Liver Transplantation in the United States: A 2004-2018 Analysis
Nabil Noureddin, Ju Dong Yang, Naim Alkhouri, et al.
Metabolism: Clinical and Experimental
|
June 28, 2024
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019
Pojsakorn Danpanichkul, Kanokphong Suparan, Priyata Dutta, et al.
Communications Medicine
|
October 30, 2024
Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria
Luis Antonio Díaz, Jeffrey V Lazarus, Eduardo Fuentes-López, et al.
Hepatology (Baltimore, Md.)
|
July 5, 2019
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
Quentin M Anstee, Eric J Lawitz, Naim Alkhouri, et al.
JAMA Network Open
|
November 6, 2025
Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes
Jeffrey V Lazarus, Leire Agirre-Garrido, Luis Antonio Díaz, et al.
The New England Journal of Medicine
|
October 20, 2021
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Sven M Francque, Pierre Bedossa, Vlad Ratziu, et al.
Journal of Hepatology
|
March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.
The Lancet. Gastroenterology & Hepatology
|
December 15, 2025
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study
Jeffrey V Lazarus, Leire Agirre-Garrido, Trenton M White, et al.
The Lancet. Gastroenterology & Hepatology
|
March 24, 2022
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
Stephen A Harrison, Manal F Abdelmalek, Guy Neff, et al.
The New England Journal of Medicine
|
February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
Page
of 31